Literature DB >> 11311687

Validation of the Johns Hopkins restless legs severity scale.

R P. Allen1, C J. Earley.   

Abstract

Determine reliability and validity of the Johns Hopkins restless legs severity scale (JHRLSS), an easily used clinical scale assessing severity of the restless legs syndrome (RLS). There is, prior to this study, no validated scale assessing the wide range of RLS severity. The JHRLSS has been used in prior studies to assess RLS severity, but has not previously been validated in relation to direct measures of the morbidity associated with RLS. A consecutive case series of 31 RLS patients was used in the study. The JHRLSS was validated by its correlation with objective measures by a polysomnogram of the sleep disturbances associated with RLS (periodic leg movements of sleep per hour (PLMS/h), and sleep efficiency). Reliability was determined from the independent ratings of two clinicians. Reliability measures for the JHRLSS based on inter-rater agreement were 0.91 (Spearman Rho) and 0.87 (Cramers V). The subjective JHRLSS correlated significantly with both objective measures of sleep: sleep efficiency (R=0.60, P<0.01) and PLMS/h (R=0.45, P=0.01). The JHRLSS provides a reliable, valid, easily used clinical assessment of RLS severity.

Entities:  

Year:  2001        PMID: 11311687     DOI: 10.1016/s1389-9457(00)00080-0

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  34 in total

Review 1.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

Review 2.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

3.  Iron deficiency anemia in infancy exerts long-term effects on the tibialis anterior motor activity during sleep in childhood.

Authors:  Patricio Peirano; Cecilia Algarin; Rodrigo Chamorro; Mauro Manconi; Betsy Lozoff; Raffaele Ferri
Journal:  Sleep Med       Date:  2012-07-04       Impact factor: 3.492

4.  Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment.

Authors:  Birgit Högl; Walter Paulus; Peter Clarenbach; Claudia Trenkwalder
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

5.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

6.  Effect of sensory stimuli on restless legs syndrome: a randomized crossover study.

Authors:  Anouk D Rozeman; Truus Ottolini; Diana C Grootendorst; Oscar J M Vogels; Roselyne M Rijsman
Journal:  J Clin Sleep Med       Date:  2014-08-15       Impact factor: 4.062

7.  Restless Leg Syndrome and Periodic Limb Movements of Sleep.

Authors:  Mark W. Mahowald
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

8.  Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome.

Authors:  Richard P Allen; Christopher J Earley; Byron C Jones; Erica L Unger
Journal:  Sleep Med       Date:  2020-02-05       Impact factor: 3.492

9.  Does frequency of restless legs syndrome and poor sleep quality increase with age in irritable bowel syndrome?

Authors:  Akif Acay; Ahmet Bal; Serdar Oruc; Taner Ozkececi; Muzaffer Sariaydin; Hayri Demirbas; Gursel Acarturk
Journal:  Wien Klin Wochenschr       Date:  2016-09-13       Impact factor: 1.704

10.  The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice.

Authors:  Rose A Franco; Ramesh Ashwathnarayan; Arshana Deshpandee; Joshua Knox; Jack Daniel; Daniel Eastwood; Jose Franco; Kia Saeian
Journal:  J Clin Sleep Med       Date:  2008-02-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.